135,345 Shares in Haleon PLC Sponsored ADR $HLN Acquired by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 135,345 shares of the company’s stock, valued at approximately $1,218,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Public Employees Retirement System of Ohio increased its stake in Haleon by 136.4% in the first quarter. Public Employees Retirement System of Ohio now owns 222,708 shares of the company’s stock worth $2,229,000 after purchasing an additional 128,493 shares during the period. Bank of America Corp DE boosted its stake in shares of Haleon by 17.0% during the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock valued at $109,452,000 after purchasing an additional 1,586,230 shares during the period. Mondrian Investment Partners LTD bought a new position in shares of Haleon in the third quarter worth about $158,737,000. Squarepoint Ops LLC bought a new position in shares of Haleon in the second quarter worth about $1,186,000. Finally, Engineers Gate Manager LP bought a new position in shares of Haleon in the second quarter worth about $1,869,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Performance

HLN stock opened at $9.04 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52. The business has a 50-day moving average price of $9.32 and a 200 day moving average price of $9.69. The company has a market capitalization of $39.76 billion, a P/E ratio of 23.19, a PEG ratio of 2.13 and a beta of 0.15. Haleon PLC Sponsored ADR has a 1-year low of $8.38 and a 1-year high of $11.28.

Analyst Ratings Changes

HLN has been the subject of a number of research analyst reports. Deutsche Bank upgraded shares of Haleon from a “sell” rating to a “hold” rating in a report on Friday, October 30th. Royal Bank Of Canada restated a “sector perform” rating on shares of Haleon in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Friday, September 25th. Berenberg Bank reiterated a “buy” rating on shares of Haleon in a report on Wednesday, August 5th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Haleon currently has a consensus rating of “Moderate Buy” and an average price target of $4.90.

Read Our Latest Report on HLN

Haleon Profile

(Free Report)

Haleon plc is a global consumer healthcare company that develops and sells nonprescription health products. Its portfolio spans oral health, pain relief, vitamins and supplements, respiratory health, digestive health, and therapeutic skin care. Its brands include Sensodyne, parodontax and Polident in oral care; Advil, Panadol and Voltaren for pain relief; and Centrum, Emergen-C and Theraflu in supplements and respiratory care. Haleon sells its products in markets around the world. Haleon became an independent public company in 2022 after separating from GSK.

Read More

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.